Clear Street Markets LLC Increases Holdings in GSK plc (NYSE:GSK)

Clear Street Markets LLC grew its stake in shares of GSK plc (NYSE:GSKFree Report) by 12.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,836 shares of the pharmaceutical company’s stock after acquiring an additional 5,729 shares during the quarter. Clear Street Markets LLC’s holdings in GSK were worth $1,921,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc boosted its stake in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares during the last quarter. BKM Wealth Management LLC bought a new stake in GSK in the 4th quarter worth about $32,000. Jones Financial Companies Lllp increased its holdings in GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares in the last quarter. Princeton Global Asset Management LLC raised its position in GSK by 54.3% in the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after buying an additional 533 shares during the last quarter. Finally, Armstrong Advisory Group Inc. lifted its stake in GSK by 189.1% during the 4th quarter. Armstrong Advisory Group Inc. now owns 1,619 shares of the pharmaceutical company’s stock valued at $60,000 after acquiring an additional 1,059 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

GSK stock traded up $0.05 during midday trading on Wednesday, reaching $41.11. 2,548,550 shares of the company’s stock traded hands, compared to its average volume of 3,612,202. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The stock has a market cap of $85.20 billion, a P/E ratio of 14.89, a PEG ratio of 1.25 and a beta of 0.66. The stock’s 50-day moving average is $42.56 and its 200 day moving average is $40.86.

GSK (NYSE:GSKGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. As a group, analysts anticipate that GSK plc will post 4.11 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.3762 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.66%. This is an increase from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is 53.26%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GSK. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, The Goldman Sachs Group initiated coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Read Our Latest Research Report on GSK

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Want to see what other hedge funds are holding GSK? Visit to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with's FREE daily email newsletter.